Global Coronary Artery Disease (CAD) Market Worth $38.17 Billion by 2028 - Increasing Demand for Medications Leading to a Rise in Retail Pharmacies

News provided by

Jun 23, 2023, 11:15 ET

DUBLIN, June 23, 2023 /PRNewswire/ -- The "Coronary Artery Disease (CAD) Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Coronary Artery Disease (CAD) Market will reach US$ 38.17 billion in 2028 from US$ 22.94 billion in 2022, growing at a CAGR of 8.86%

The increasing prevalence of CAD due to aging populations, unhealthy lifestyles, and rising rates of obesity and diabetes is driving growth in the coronary artery disease market. Therefore, there is a rising need for diagnostic tools and treatments, such as medication, medical devices, and surgical procedures.

Furthermore, advances in medical technology and research have also led to new and more effective therapies for CAD, including drug-eluting stents and minimally invasive procedures. In addition, tailoring treatment plans to individual patients based on their unique factors is becoming increasingly popular, known as personalized medicine.

Anti-platelet Drugs Have Hegemony in the Coronary Artery Disease (CAD) Market

Drug types in the coronary artery disease (CAD) market are antiplatelets, beta-blockers, calcium antagonists, anticoagulants, and others. Antiplatelet drugs are the dominant therapy in the coronary artery disease market, as they are widely used to prevent blood clots that can lead to heart attacks and strokes in patients with CAD.

In addition, they have been proven effective in reducing the risk of recurrent cardiovascular events and have a low risk of side effects, making them a safe long-term option for CAD patients. To manage CAD, use antiplatelet drugs in combination with other therapies such as statins, beta-blockers, and ACE inhibitors.

Anticoagulant drugs for coronary artery disease have grown due to various factors. They prevent blood clots in CAD patients, the development of newer medications like DOACs, the increasing prevalence of CAD, and the demand for effective anticoagulant therapies. Personalized medicine has also contributed to growth, as tailored treatment plans can optimize drug use and improve patient outcomes.

Increasing Demand for Medications Has Led to the Growth of Retail Pharmacies

The coronary artery disease (CAD) market has hospital pharmacies, retail pharmacies, and online pharmacies distribution channels mainly. The growth of retail pharmacies in the coronary artery disease market is due to the increasing demand for medications used in CAD treatment and management, the aging population, and technological advancements.

These have expanded retail pharmacies' product offerings and services, making them a more attractive option for patients seeking comprehensive healthcare services. In addition, changes in healthcare policy and reimbursement models have also incentivized patients to seek care in retail pharmacies.

However, hospital pharmacies are an authority in the coronary artery disease (CAD) market as they are often the first point of contact for CAD patients, particularly those with acute conditions. They have access to a broader range of medications and specialized products and highly trained professionals with expertise in CAD management.

In addition, the trend toward value-based healthcare has led to the development of integrated healthcare systems, making hospital pharmacies integral in providing various services in a single location.

China Coronary Artery Disease (CAD) Market has grown because of an aging population and the growing prevalence of chronic ailments like obesity and diabetes. U.S., France, Germany, China, United Kingdom, Japan, Saudi Arabia, and Russia are the countries that comprise the coronary artery disease (CAD) market.

Expanding China's healthcare system and investing in medical infrastructure have improved CAD treatment and management. Furthermore, the rise of China's middle class has created opportunities for foreign and domestic pharmaceutical companies to enter the Chinese coronary artery disease (CAD) market.

In addition, the government's focus on promoting innovation and research in healthcare has led to new CAD therapies and management strategies, including TCM. Finally, policies promoting healthy lifestyles and disease management programs have contributed to the coronary artery disease (CAD) market growth.

The US dominates the CAD market due to its high prevalence of risk factors for CAD, resulting in a significant need for CAD treatments. CAD is the main reason for mortality in the US. The National Centre of Biotechnology Information (NCBI) report of 2023 states that coronary artery disease (CAD) is responsible for approximately 610,000 deaths annually accounting for an estimated 1 in 4 deaths in the United States, making it the leading cause of mortality.

The country also has advanced medical infrastructure, leading pharmaceutical and medical device companies, and heavy investment in healthcare research and development. Moreover, the US prioritizes preventive healthcare, focusing more on CAD prevention and management.

Key Players

AstraZeneca PLC, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, Merck & Co. Inc, Viatris, Sanofi, and Amgen are prominent in the coronary artery disease (CAD) market.

Company Analysis: Overview, Recent Developments, & Revenue

AstraZeneca PLC
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
Merck & Co. Inc.
Viatris
Sanofi
Amgen

Drug Types - Market breakup from 5 Viewpoints:

Antiplatelets
Beta-blockers
Calcium antagonists
Anticoagulants
Others

Distribution Channels - Market breakup from 3 Viewpoints:

Hospital pharmacies
Retail pharmacies
Online pharmacies

Countries - Market breakup from 8 Viewpoints:

United States
France
Germany
China
United Kingdom
Japan
Saudi Arabia
Russia

Clinical Trial Drugs - Overview for 2 Drugs:

Colchicine
Rivaroxaban 2.5 Mg Oral Tablet

For more information about this report visit https://www.researchandmarkets.com/r/jztilc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets